Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samra Turajlic

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
Immuno-Oncology Technology|June 27, 2022
Tumour mutational burden: primary versus metastatic tissue creates systematic biasDesiree Schnidrig, Samra Turajlic, Kevin Litchfield
Cancer Discovery|August 3, 2017
The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset ReleasedKevin Litchfield, Samra Turajlic, Charles Swanton
British Journal of Cancer|February 18, 2020
New survival standards for advanced melanomaLavinia Spain, James Larkin, Samra Turajlic
Biochimica Et Biophysica Acta|April 2, 2015
Inferring mutational timing and reconstructing tumour evolutionary historiesSamra Turajlic, Nicholas McGranahan, Charles Swanton
Seminars in Cancer Biology|April 5, 2021
Predictive biomarkers for response to immune checkpoint inhibitionBenjamin Shum, James Larkin, Samra Turajlic
European Urology Focus|February 3, 2020
Evolution of Renal Cell CarcinomaZayd Tippu, Lewis Au, Samra Turajlic
Cell|December 23, 2022
Relatlimab and nivolumab in the treatment of melanomaLewis Au, James Larkin, Samra Turajlic
The Journal of Experimental Medicine|September 16, 2018
Kidney cancer: The next decadeSamra Turajlic, Charles Swanton, Chris Boshoff
Therapeutic Advances in Medical Oncology|July 7, 2018
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selectionMichael Flynn, Lisa Pickering, James Larkin, et al.
Nature Reviews. Genetics|October 30, 2019
Author Correction: Resolving genetic heterogeneity in cancerSamra Turajlic, Andrea Sottoriva, Trevor Graham, et al.
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
Immuno-Oncology Technology|June 27, 2022
Tumour mutational burden: primary versus metastatic tissue creates systematic biasDesiree Schnidrig, Samra Turajlic, Kevin Litchfield
Cancer Discovery|August 3, 2017
The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset ReleasedKevin Litchfield, Samra Turajlic, Charles Swanton
British Journal of Cancer|February 18, 2020
New survival standards for advanced melanomaLavinia Spain, James Larkin, Samra Turajlic
Biochimica Et Biophysica Acta|April 2, 2015
Inferring mutational timing and reconstructing tumour evolutionary historiesSamra Turajlic, Nicholas McGranahan, Charles Swanton
Seminars in Cancer Biology|April 5, 2021
Predictive biomarkers for response to immune checkpoint inhibitionBenjamin Shum, James Larkin, Samra Turajlic
European Urology Focus|February 3, 2020
Evolution of Renal Cell CarcinomaZayd Tippu, Lewis Au, Samra Turajlic
Cell|December 23, 2022
Relatlimab and nivolumab in the treatment of melanomaLewis Au, James Larkin, Samra Turajlic
The Journal of Experimental Medicine|September 16, 2018
Kidney cancer: The next decadeSamra Turajlic, Charles Swanton, Chris Boshoff
Therapeutic Advances in Medical Oncology|July 7, 2018
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selectionMichael Flynn, Lisa Pickering, James Larkin, et al.
Nature Reviews. Genetics|October 30, 2019
Author Correction: Resolving genetic heterogeneity in cancerSamra Turajlic, Andrea Sottoriva, Trevor Graham, et al.
Pageof 13